# Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

> clinical trial · VERIFIED · 2026-08-10

Status: ACTIVE_NOT_RECRUITING · Sponsor: M.D. Anderson Cancer Center · Condition: Blastoid Variant Mantle Cell Lymphoma

- Company: M.D. Anderson Cancer Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT03946878

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.